Active, Not Recruiting
The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung - CV185-640
Updated: 5 December, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Adults participants at date of admission - Primary presentation consistent with PE followed by objectively-confirmed acute PE - Received anti-coagulation upon diagnosis of PE during study period and in receipt of anti-coagulation at discharge Exclusion Criteria: - PE diagnosed during a hospital admission for a reason other than PE during the study period - Patients receiving anticoagulation at the time of presentation - Patients presenting outside the defined study period Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
